Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Format: | Article |
---|---|
Language: | English |
Published: |
BMJ Publishing Group
2022-05-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/5/e004699corr1.full |
Similar Items
-
Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01) -
FULMINANT MYOCARDITIS IN THE DOCTOR'S PRACTICE
by: M. R. Bakhchoyan, et al.
Published: (2016-12-01) -
Mechanical bridge to recovery in fulminant myocarditis.
by: Westaby, S, et al.
Published: (2000) -
Characteristics of Electrocardiogram Findings in Fulminant Myocarditis
by: Mei-Yan Dai, et al.
Published: (2023-06-01) -
Fulminant guillain-barré syndrome with myocarditis
by: Ajay Mishra, et al.
Published: (2014-01-01)